# Development of seropositivity to SARS-CoV-2 over the course of the COVID-19 pandemic in adolescents in a longitudinal cohort study in Cebu, Philippines

**Authors:** Jedas Veronica Daag, Gianne Lariz Magsakay, Silvia Blanco Rivera, Ma. Gladys Nicole Daque, Irish Lobitana, Marla Angela Lariana, Kiarah Louise Florendo, Maria Vinna Crisostomo, Ana Coello Escoto, Lakshmanane Premkumar, Rosemary Aogo, Jacqueline Deen, Leah Katzelnick, Michelle Ylade

PMC · DOI: 10.1371/journal.pgph.0005961 · PLOS Global Public Health · 2026-02-26

## TL;DR

This study tracks how many adolescents in the Philippines developed immunity to SARS-CoV-2 through infection and vaccination during the pandemic.

## Contribution

The study provides new insights into the development of SARS-CoV-2 seropositivity in adolescents in a developing country over time.

## Key findings

- 17.0% of acute febrile episodes in the cohort were SARS-CoV-2 RT-PCR positive.
- 30.3% of tested adolescents were seropositive for SARS-CoV-2 RBD antibodies in 2021.
- 96.6% of the cohort was seropositive by late-pandemic sample in 2022–2023, with vaccination and site as predictors.

## Abstract

COVID-19 was first reported in the Philippines in January 2020 and the country experienced several COVID-19 waves. Little is known on the seroprevalence of SARS-CoV-2 among adolescents in a developing country such as the Philippines. In this study, we incorporated testing for acute COVID-19 and SARS-CoV-2 seropositivity in an ongoing dengue study of 9- to 14-year-old participants enrolled in 2017. Acute febrile episodes were detected through active surveillance and a nasopharyngeal swab was obtained for SARS-CoV-2 RT-PCR. Before COVID-19 vaccination was offered, we tested a subset of sera obtained in 2021 for SARS-CoV-2 receptor binding domain (RBD) antibodies. Development of SARS-CoV-2 seropositivity acquired through natural infection and vaccination was conducted by measuring antibodies pre- (2018–2019), early- (2019–2020), and late-pandemic (2022–2023) in those with matched samples. From July 2021-October 2022, we recorded 29 acute febrile illness episodes in the cohort and 17.0% were SARS-CoV-2 RT-PCR positive. In the subset of 499 samples tested for SARS-CoV-2 RBD antibodies in 2021, 30.3% were seropositive. Among these, 4.0% were seropositive in 2018–2019, and 11.0% had seroconverted by 2020. Interestingly, 74.0% experienced antibody waning between 2020 and 2021 sampling. By 2022, 345/499 children received full COVID-19 vaccination and 13/499 was partially vaccinated, with 96.6% SARS-CoV-2 seropositive by late-pandemic sample in 2022–2023. Vaccination and site were predictors of SARS-CoV-2 RBD antibodies. These findings suggest both variation in local transmission over time as well as association of vaccination with the development of SARS-CoV-2 immunity in adolescents in the Philippines.

## Linked entities

- **Diseases:** SARS-CoV-2 (MONDO:0100096), dengue (MONDO:0005502), COVID-19 (MONDO:0100096)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** N (nucleocapsid phosphoprotein) [NCBI Gene 43740575], S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}
- **Diseases:** coronavirus infections (MESH:D018352), infection (MESH:D007239), COVID-19 (MESH:D000086382), cough (MESH:D003371), abdominal pain (MESH:D015746), Acute febrile illness (MESH:D000071072), dengue (MESH:D003715), seropositive (MESH:D006679), febrile illness (MESH:D005334)
- **Chemicals:** Bogo (-), Tween 20 (MESH:D011136), p-nitrophenyl phosphate (MESH:C008644)
- **Species:** Homo sapiens (human, species) [taxon 9606], Gammacoronavirus (genus) [taxon 694013], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Candidatus Accumulibacter adiacens (species) [taxon 2954378]
- **Cell lines:** OC43 — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_A1GZ), HKU1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), 229E — Canis lupus familiaris (Dog), Canine mammary carcinoma, Cancer cell line (CVCL_L334)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12944793/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944793/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12944793/full.md

---
Source: https://tomesphere.com/paper/PMC12944793